Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA)

被引：141

作者：

Hamanishi, Junzo ^{[1
]}

Takeshima, Nobuhiro ^{[2
,3
]}

Katsumata, Noriyuki ^{[4
]}

Ushijima, Kimio ^{[5
]}

Kimura, Tadashi ^{[6
]}

Takeuchi, Satoshi ^{[7
,8
]}

Matsumoto, Koji ^{[9
]}

Ito, Kimihiko ^{[10
]}

Mandai, Masaki ^{[1
,11
]}

Nakai, Hidekatsu ^{[11
]}

Sakuragi, Noriaki ^{[12
,13
]}

Watari, Hidemichi ^{[12
]}

Takahashi, Nobutaka ^{[14
]}

Kato, Hidenori ^{[15
]}

Hasegawa, Kosei ^{[16
]}

Yonemori, Kan ^{[17
]}

Mizuno, Mika ^{[18
,19
]}

Takehara, Kazuhiro ^{[20
]}

Niikura, Hitoshi ^{[21
,22
]}

Sawasaki, Takashi ^{[23
,24
]}

Nakao, Sari ^{[25
]}

Saito, Toshiaki ^{[26
]}

Enomoto, Takayuki ^{[27
]}

Nagase, Satoru ^{[28
]}

Suzuki, Nao ^{[29
]}

Matsumoto, Takashi ^{[30
]}

Kondo, Eiji ^{[31
]}

Sonoda, Kenzo ^{[32
,33
]}

Aihara, Satomi ^{[34
,35
]}

Aoki, Yoichi ^{[36
]}

Okamoto, Aikou ^{[37
]}

Takano, Hirokuni ^{[38
]}

Kobayashi, Hiroshi ^{[39
,40
]}

Kato, Hisamori ^{[41
]}

Terai, Yoshito ^{[42
,43
]}

Takazawa, Akira ^{[44
]}

Takahashi, Yusuke ^{[45
]}

Namba, Yoshinobu ^{[46
]}

Aoki, Daisuke ^{[47
]}

Fujiwara, Keiichi ^{[16
]}

Sugiyama, Toru ^{[7
,48
]}

Konishi, Ikuo ^{[49
]}

机构：

[1] Kyoto Univ, Dept Gynecol & Obstet, Grad Sch Med, Kyoto, Japan

[2] JFCR, Dept Gynecol, Canc Inst Hosp, Tokyo, Japan

[3] Int Univ Hlth & Welf Hosp, Dept Obstet & Gynecol, Otawara, Japan

[4] Musashikosugi Hosp, Dept Med Oncol, Nippon Med Sch, Kawasaki, Kanagawa, Japan

[5] Kurume Univ, Dept Obstet & Gynecol, Sch Med, Kurume, Fukuoka, Japan

[6] Osaka Univ, Dept Obstet & Gynecol, Grad Sch Med, Suita, Osaka, Japan

[7] Iwate Med Univ Hosp, Dept Obstet & Gynecol, Morioka, Iwate, Japan

[8] Kobe Tokushukai Hosp, Dept Gynecol, Kobe, Hyogo, Japan

[9] Hyogo Canc Ctr, Dept Med Oncol, Akashi, Hyogo, Japan

[10] Kansai Rosai Hosp, Dept Obstet & Gynecol, Amagasaki, Hyogo, Japan

[11] Kindai Univ, Dept Obstet & Gynecol, Fac Med, Osakasayama, Japan

[12] Hokkaido Univ, Dept Obstet & Gynecol, Grad Sch Med, Sapporo, Hokkaido, Japan

[13] Otaru Gen Hosp, Dept Gynecol, Otaru, Hokkaido, Japan

[14] Shizuoka Canc Ctr, Div Gynecol, Shizuoka, Japan

[15] Hokkaido Canc Ctr, Dept Gynecol, Sapporo, Hokkaido, Japan

[16] Saitama Med Univ, Dept Gynecol Oncol, Int Med Ctr, Hidaka, Japan

[17] Natl Canc Ctr, Dept Breast & Med Oncol, Tokyo, Japan

[18] Aichi Canc Ctr Hosp, Dept Obstet & Gynecol, Nagoya, Aichi, Japan

[19] Kagoshima Univ Hosp, Dept Obstet & Gynecol, Kagoshima, Japan

[20] Natl Hosp Org Shikoku Canc Ctr, Dept Gynecol Oncol, Matsuyama, Ehime, Japan

[21] Tohoku Univ, Dept Obstet & Gynecol, Grad Sch Med, Sendai, Miyagi, Japan

[22] Natl Hosp Org Sendai Med Ctr, Dept Obstet & Gynecol, Sendai, Miyagi, Japan

[23] Natl Hosp Org Kure Med Ctr, Dept Obstet & Gynecol, Kure, Japan

[24] SAWASAKI Obstet Gynecol Clin, Kure, Japan

[25] Univ Tsukuba Hosp, Fac Med, Dept Obstet & Gynecol, Tsukuba, Ibaraki, Japan

[26] Natl Hosp Org Kyushu Canc Ctr, Gynecol Serv, Fukuoka, Fukuoka, Japan

[27] Niigata Univ, Dept Obstet & Gynecol, Grad Sch Med & Dent Sci, Niigata, Japan

[28] Yamagata Univ Hosp, Dept Obstet & Gynecol, Yamagata, Japan

[29] St Marianna Univ, Dept Obstet & Gynecol, Sch Med, Kawasaki, Kanagawa, Japan

[30] Ehime Univ Hosp, Dept Obstet & Gynecol, Toon, Japan

[31] Mie Univ Hosp, Dept Obstet & Gynecol, Tsu, Mie, Japan

[32] Kyushu Univ Hosp, Dept Obstet & Gynecol, Fukuoka, Fukuoka, Japan

[33] Natl Hosp Org Kyushu Canc Ctr, Dept Gynecol Oncol, Fukuoka, Fukuoka, Japan

[34] Saga Univ Hosp, Fac Med, Dept Obstet & Gynecol, Saga, Japan

[35] Eguchi Hosp, Dept Med Oncol, Saga, Japan

[36] Univ Ryukyus Hosp, Dept Obstet & Gynecol, Nishihara, Okinawa, Japan

[37] Jikei Univ Hosp, Dept Obstet & Gynecol, Tokyo, Japan

[38] Jikei Univ, Dept Obstet & Gynecol, Kashiwa Hosp, Kashiwa, Chiba, Japan

[39] Nara Med Univ Hosp, Dept Obstet & Gynecol, Kashihara, Nara, Japan

[40] Ms Clin MayOne, Kashihara, Nara, Japan

[41] Kanagawa Canc Ctr, Dept Gynecol, Yokohama, Kanagawa, Japan

[42] Osaka Med Coll Hosp, Dept Gynecol Oncol, Takatsuki, Osaka, Japan

[43] Kobe Univ, Obstet & Gynecol, Grad Sch Med, Kobe, Hyogo, Japan

[44] Ono Pharmaceut Co Ltd, Data Sci, Osaka, Japan

[45] Ono Pharmaceut Co Ltd, Oncol Clin Dev Unit, Osaka, Japan

[46] Ono Pharmaceut Co Ltd, Clin Sci, Osaka, Japan

[47] Keio Univ, Dept Obstet & Gynecol, Sch Med, Tokyo, Japan

[48] St Marys Hosp, Dept Obstet & Gynecol, Kurume, Fukuoka, Japan

[49] Natl Hosp Org Kyoto Med Ctr, Kyoto, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 33期

关键词：

PHASE-III TRIAL; ANTI-PD-1; ANTIBODY; ANTITUMOR-ACTIVITY; CHEMOTHERAPY; SAFETY; AVELUMAB; CELLS;

D O I：

10.1200/JCO.21.00334

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PURPOSE This phase III, multicenter, randomized, open-label study investigated the efficacy and safety of nivolumab versus chemotherapy (gemcitabine [GEM] or pegylated liposomal doxorubicin [PLD]) in patients with platinum-resistant ovarian cancer. MATERIALS AND METHODS Eligible patients had platinum-resistant epithelial ovarian cancer, received <= 1 regimen after diagnosis of resistance, and had an Eastern Cooperative Oncology Group performance score of <= 1. Patients were randomly assigned 1:1 to nivolumab (240 mg once every 2 weeks [as one cycle]) or chemotherapy (GEM 1000 mg/m(2) for 30 minutes [once on days 1, 8, and 15] followed by a week's rest [as one cycle], or PLD 50 mg/m(2) once every 4 weeks [as one cycle]). The primary outcome was overall survival (OS). Secondary outcomes included progression-free survival (PFS), overall response rate, duration of response, and safety. RESULTS Patients (n = 316) were randomly assigned to nivolumab (n = 157) or GEM or PLD (n = 159) between October 2015 and December 2017. Median OS was 10.1 (95% CI, 8.3 to 14.1) and 12.1 (95% CI, 9.3 to 15.3) months with nivolumab and GEM or PLD, respectively (hazard ratio, 1.0; 95% CI, 0.8 to 1.3; P = .808). Median PFS was 2.0 (95% CI, 1.9 to 2.2) and 3.8 (95% CI, 3.6 to 4.2) months with nivolumab and GEM or PLD, respectively (hazard ratio, 1.5; 95% CI, 1.2 to 1.9; P = .002). There was no statistical difference in overall response rate between groups (7.6% v 13.2%; odds ratio, 0.6; 95% CI, 0.2 to 1.3; P = .191). Median duration of response was numerically longer with nivolumab than GEM or PLD (18.7 v 7.4 months). Fewer treatment-related adverse events were observed with nivolumab versus GEM or PLD (61.5% v 98.1%), with no additional or new safety risks. CONCLUSION Although well-tolerated, nivolumab did not improve OS and showed worse PFS compared with GEM or PLD in patients with platinum-resistant ovarian cancer. (C) 2021 by American Society of Clinical Oncology

引用

页码：3671 / +

页数：16

共 37 条

[11] The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition [J].

Hegde, Priti S. ;

Karanikas, Vaios ;

Evers, Stefan .

CLINICAL CANCER RESEARCH, 2016, 22 (08) :1865-1874

[12] Targeting Programmed Cell Death 1 in Ovarian Cancer [J].

Homicsko, Krisztian ;

Coukos, George .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (34) :3987-+

[13] INDUCED EXPRESSION OF PD-1, A NOVEL MEMBER OF THE IMMUNOGLOBULIN GENE SUPERFAMILY, UPON PROGRAMMED CELL-DEATH [J].

ISHIDA, Y ;

AGATA, Y ;

SHIBAHARA, K ;

HONJO, T .

EMBO JOURNAL, 1992, 11 (11) :3887-3895

[14] Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade [J].

Iwai, Y ;

Ishida, M ;

Tanaka, Y ;

Okazaki, T ;

Honjo, T ;

Minato, N .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (19) :12293-12297

[15]

Klein J. P., 2006, Survival analysis: techniques for censored and truncated data, DOI DOI 10.1007/B97377

[16] TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib plus pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)-Results from ROC cohort. [J].

Konstantinopoulos, Panagiotis A. ;

Waggoner, Steven E. ;

Vidal, Gregory A. ;

Mita, Monica M. ;

Fleming, Gini F. ;

Holloway, Robert W. ;

Van Le, Linda ;

Sachdev, Jasgit C. ;

Chapman-Davis, Eloise ;

Colon-Otero, Gerardo ;

Penson, Richard T. ;

Matulonis, Ursula A. ;

Kim, Young B. ;

Moore, Kathleen N. ;

Swisher, Elizabeth M. ;

Dezube, Bruce Jeffrey ;

Wang, Jing Y. ;

Buerstatte, Nathan ;

Arora, Sujata ;

Munster, Pamela N. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

[17] Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE) [J].

Kurzeder, Christian ;

Bover, Isabel ;

Marme, Frederik ;

Rau, Joern ;

Pautier, Patricia ;

Colombo, Nicoletta ;

Lorusso, Domenica ;

Ottevanger, Petronella ;

Bjurberg, Maria ;

Marth, Christian ;

Barretina-Ginesta, Pilar ;

Vergote, Ignace ;

Floquet, Anne ;

del Campo, Josep M. ;

Mahner, Sven ;

Bastiere-Truchot, Lydie ;

Martin, Nicolas ;

Oestergaard, Mikkel Z. ;

Kiermaier, Astrid ;

Schade-Brittinger, Carmen ;

Polleis, Sandra ;

du Bois, Andreas ;

Gonzalez-Martin, Antonio .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (21) :2516-+

[18] Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study [J].

Lampert, Erika J. ;

Zimmer, Alexandra ;

Padget, Michelle ;

Cimino-Mathews, Ashley ;

Nair, Jayakumar R. ;

Liu, Yingmiao ;

Swisher, Elizabeth M. ;

Hodge, James W. ;

Nixon, Andrew B. ;

Nichols, Erin ;

Bagheri, Mohammad H. ;

Levy, Elliott ;

Radke, Marc R. ;

Lipkowitz, Stanley ;

Annunziata, Christina M. ;

Taube, Janis M. ;

Steinberg, Seth M. ;

Lee, Jung-Min .

CLINICAL CANCER RESEARCH, 2020, 26 (16) :4268-4279

[19] Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer [J].

Le Saux, Olivia ;

Ray-Coquard, Isabelle ;

Labidi-Galy, S. Intidhar .

SEMINARS IN CANCER BIOLOGY, 2021, 77 :127-143

[20] Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Ledermann, J. A. ;

Raja, F. A. ;

Fotopoulou, C. ;

Gonzalez-Martin, A. ;

Colombo, N. ;

Sessa, C. .

ANNALS OF ONCOLOGY, 2013, 24 :24-32

← 1 2 3 4 →